top of page


June 3, 2024

Inhalon Biopharma to Provide Update on Inhaled Monoclonal Antibody Therapy Platform at BIO International Convention  Read More

April 25, 2024

Inhalon Biopharma to Share Progress on Inhaled Monoclonal Antibody Therapy at 9th Annual Inhalation and Respiratory Drug Delivery Congress  Read More

March 20, 2024

Inhalon Biopharma Announces Positive Results from Study Demonstrating Superior Safety and Efficacy of its Inhaled Antibody Platform Over Systemic Dosing  Read More

March 14, 2024

Inhalon Biopharma Announces Two Publications Advancing its Inhaled Antibody Treatment Platform for Acute Respiratory Infections Read More

January 8, 2024

Inhalon Biopharma to Present on Product Development Pipeline at Biotech Showcase  Read More

November 15, 2023

Inhalon Biopharma Secures U.S. Army Medical Research and Development Command Award to Support Development of Inhaled Therapeutics for Treatment of COVID-19  Read More

November 1, 2023

Inhalon Biopharma Expands Therapeutic Horizons with Licensing of hMPV Antibodies from the University of Georgia  Read More

October 6, 2023

Inhalon Biopharma to Share Progress in Development of Inhaled Antibody Platform at the Bio Investor Forum and Bio Europe  Read More

June 30, 2022

Inhalon Biopharma Closes Series A Financing to Further their Study of Inhaled Antibodies  Read More

October 7, 2021

Inhalon Doses First Patient in Phase 1 Study of Inhaled IN‑006 to Treat COVID-19  Read More

July 22, 2021

Inhalon Collaborates with Celltrion, Inc. to Develop Nebulized Form of Regdanvimab to Treat COVID-19 Patients at Home  Read More

July 16, 2021

Inhalon Biopharma Appoints Jeff Hutchins, Ph.D. as Chief Development Officer  Read More

May 26, 2021

Inhalon Biopharma Receives $7 Million from USAMRDC to Study Inhaled “Muco-trapping” Antibody for the Treatment of COVID-19  Read More

bottom of page